Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REASSURE: Secukinumab in Active Rheumatoid Arthritis
NCT01377012Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2011
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of secukinumab in rheumatoid arthritis (RA), sponsored by Novartis. Started Aug 2011; status: completed.
02
Drugs
secukinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01377012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01377012.